Merck Clears Major Hurdle in Eleven Point Three Billion Dollar Bio-Techne Acquisition

Shareholders of Bio-Techne Corporation voted on September 23 to approve the definitive merger agreement with Merck KGaA, marking a critical milestone toward completing the German pharmaceutical giant's largest acquisition in over a decade. The all-cash deal values the Minneapolis-based life sciences company at approximately eleven point three billion dollars.

Merck KGaA is offering seventy-three dollars per share for Bio-Techne, representing a thirty-six percent premium over the company's one-month average share price prior to the June announcement. The transaction represents Merck's most ambitious move since its seventeen billion dollar purchase of Sigma-Aldrich in 2015, and the first major acquisition under new CEO Kai Beckmann.

Bio-Techne operates as a global provider of high-purity recombinant proteins, cytokines, antibodies, and multiplex immunoassay platforms. The company's portfolio includes its Simple Plex and Ella automated protein analysis systems, which play critical roles across drug discovery, cell therapy manufacturing, and clinical diagnostics workflows. Bio-Techne generated one point twenty-two billion dollars in fiscal 2025 net sales and employs over three thousand people worldwide.

The acquisition positions Merck KGaA to expand its upstream capabilities in biologics development and advanced therapy manufacturing. Bio-Techne's GMP-grade and research-use-only proteins, including interleukins, growth factors, and cell culture reagents, make it a critical supplier for companies developing next-generation biologics and cell therapies.

Beckmann framed the deal as an important milestone toward delivering on Merck's mid- to long-term strategic agenda. The company intends to fund the transaction through a combination of existing cash reserves and proceeds from new debt issuance, a financing structure that reflects confidence in the strategic rationale despite the substantial price tag.

The shareholder approval follows the expiration of the US Hart-Scott-Rodino antitrust waiting period on September 18, removing two major conditions to closing. However, regulatory reviews in other jurisdictions remain ongoing. Bio-Techne continues to expect the transaction to close in late 2026 or early 2027, pending clearance from international regulators.

The deal underscores consolidation trends in the life sciences tools sector as major pharmaceutical companies seek to secure supply chains and expand capabilities in biologics manufacturing. Bio-Techne's specialized protein products and automated analysis platforms fill strategic gaps in Merck's existing portfolio while delivering immediate revenue from an established commercial operation.